Key result
Higher admission BNP linked to ~121% greater risk of new cardiac events in ICU CKD.
Why the study?
Limited data are available regarding the diagnostic and prognostic utility of brain natriuretic peptide (BNP) in ICU patients with chronic kidney disease (CKD).
Do admission BNP levels predict new cardiac events in patients with chronic kidney disease admitted to the ICU?
Cohort (n=169)
No
Do admission BNP levels predict new cardiac events in patients with chronic kidney disease admitted to the ICU?
Hazard Ratio: 2.212 (95% CI 1.145–4.276)
p-value: p=0.018
Admission BNP levels can help detect acute decompensated heart failure and predict future cardiac events in ICU patients with chronic kidney disease.
INTRODUCTION: Limited data are available regarding the diagnostic and prognostic utility of brain natriuretic peptide (BNP) in patients with chronic kidney disease (CKD) in the intensive care unit (ICU) setting. METHODS: All patients with CKD and a serum creatinine (Cr) of 2.0 mg/dl or higher admitted to the ICU between January 2006 and September 2007 were enrolled in this study. The CKD group was divided according to the presence or absence of acute decompensated heart failure (ADHF) into CKD + ADHF and CKD-ADHF groups, respectively. Other patients with ADHF having low Cr (<1.2 mg/dl) in the coronary care unit were also recruited as a control group during the same period. BNP levels at the time of admission (admission BNP) were compared amongst these groups. We then sought to determine whether BNP levels could predict the outcome in patients with CKD. RESULTS: Of 136 patients with CKD for whom data were available, including 58 on dialysis (42.6%), 81 (59.6%) had ADHF and their estimated glomerular filtration rate (eGFR) was 12.8 +/- 7.3 ml/min/1.73 m2. BNP levels at admission were 2708.6 +/- 1246.9, 567.9 +/- 491.7 and 1418.9 +/- 1126.5 pg/ml in the CKD + ADHF, CKD - ADHF and control groups (n = 33), respectively (P = 0.000). The optimal cutoff level in patients with CKD was 1020.5 pg/ml (area under the curve = 0.944) to detect ADHF from the receiver operating characteristic (ROC) curve. This level was not associated with in-hospital mortality, all-cause death or a composite event (all-cause death and/or new cardiac event). However, a borderline significant association was observed with new cardiac events (hazard ratio (HR) = 4.551; P = 0.078) during the follow-up period (521.1 +/- 44.7 days). Furthermore, continuous variables of BNP and BNP quartiles were significantly associated with new cardiac events in the multivariate Cox model (HR = 1.001, P = 0.041; HR = 2.212, P = 0.018). CONCLUSIONS: The findings suggest that the level of BNP at the time of admission may be a useful marker for detecting ADHF and predicting cardiac events in patients with CKD in the ICU setting.
No takes yet. Share an insight, caveat, or question.
Park et al. (2009) conducted a cohort in Chronic kidney disease in the intensive care unit (n=169). Brain natriuretic peptide (BNP) levels at admission vs. Lower BNP levels was evaluated on New cardiac events (readmission due to heart failure, acute coronary syndrome, or sudden death) (HR 2.212, 95% CI 1.145-4.276, p=0.018). Higher admission BNP levels (by quartile) were significantly associated with an increased risk of new cardiac events in ICU patients with chronic kidney disease (HR 2.212).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: